Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 32 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 9402935

    Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs

    Lutonix, Inc. · Granted Aug 2, 2016 · Expires Jul 28, 2036

    granted

  2. US 9402898

    Stabilized formulations containing anti-Ang2 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 2, 2016 · Expires Jul 28, 2036

    granted

  3. US 9382327

    Anti-CD20 antibodies and methods of use

    VACCINEX, INC. · Granted Jul 5, 2016 · Expires Jun 30, 2036

    granted

  4. US 9371383

    Anti-ASIC1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2016 · Expires Jun 16, 2036

    granted

  5. US 9359429

    Anti-cyanobacteria recombinant antibody polypeptide, gene thereof, and preparation method thereof

    PROTEIN DESIGN LAB, LTD. · Granted Jun 7, 2016 · Expires Jun 2, 2036

    granted

  6. US 9359447

    Anti-mesothelin chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 7, 2016 · Expires Jun 2, 2036

    granted

  7. US 9351970

    Anti-viral pyrimidine nucleoside analogues

    University College Cardiff Consultants Limited · Granted May 31, 2016 · Expires May 26, 2036

    granted

  8. US 9345748

    Anti-SSX-2 T cell receptors and related materials and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 24, 2016 · Expires May 19, 2036

    granted

  9. US 9334522

    Agents and methods to elicit anti-tumor immune response

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted May 10, 2016 · Expires May 5, 2036

    granted

  10. US 9326950

    Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 3, 2016 · Expires Apr 28, 2036

    granted

  11. US 9321811

    Further novel anti-parasitic compounds

    The Regents of the University of California · Granted Apr 26, 2016 · Expires Apr 21, 2036

    granted

  12. US 9321834

    Anti-malarial compositions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 26, 2016 · Expires Apr 21, 2036

    granted

  13. US 9316646

    Anti-human ROR1 antibodies

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 19, 2016 · Expires Apr 14, 2036

    granted

  14. US 9308256

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted

  15. US 9309298

    Anti-bacterial polypeptides and pathogen specific synthetic antibodies

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted

  16. US 9309535

    Combination anti-HIV vectors, targeting vectors, and methods of use

    The Regents of the University of California · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted

  17. US 9302015

    Anti-PRLR antibodies and methods for killing PRLR-expressing cells

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  18. US 9284380

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 15, 2016 · Expires Mar 10, 2036

    granted

  19. US 9278110

    Anti-regurgitation and/or anti-gastrooesophageal reflux composition, preparation and uses

    UNITED PHARMACEUTICALS · Granted Mar 8, 2016 · Expires Mar 3, 2036

    granted

  20. US 9272137

    Transdermal methods and systems for the delivery of anti-migraine compounds

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted

  21. US 9273136

    Fully human anti-human NKG2D monoclonal antibodies

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted

  22. US 9273143

    Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted

  23. US 9265827

    Anti-PDGFR-beta antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 23, 2016 · Expires Feb 18, 2036

    granted

  24. US 9266960

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 23, 2016 · Expires Feb 18, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.